Quantitative analysis for Galectin Therapeutics Inc. (GALT) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Hold (48.0) (grade C). 26 signals analyzed (22 differentiated alt-data).
GALT stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $2.32 | $2.24 | $2.25 |
| 2026-05-11 | $2.40 | $2.08 | $2.21 |
| 2026-05-21 | $2.56 | $2.15 | $2.52 |
| 2026-06-03 | $2.43 | $2.30 | $2.35 |
| 2026-06-15 | $2.78 | $2.58 | $2.62 |
| 2026-06-26 | $5.03 | $4.18 | $4.99 |
| 2026-07-09 | $4.96 | $4.30 | $4.37 |
| 2026-07-21 | $4.15 | $3.84 | $3.85 |
| 2026-07-31 | $3.33 | $2.95 | $2.97 |
| 2026-08-12 | $3.26 | $3.12 | $3.14 |
| 2026-08-24 | $3.97 | $3.58 | $3.88 |
| 2026-09-03 | $4.60 | $4.22 | $4.35 |
How Galectin Therapeutics Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CRDL | Cardiol Therapeutics Inc. | $145M | — |
| IVVD | Invivyd, Inc. | $145M | — |
| VXRT | Vaxart, Inc. | $148M | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $142M | — |
View all Health Care stocks by valuation and signals →
Galectin Therapeutics Inc. (GALT) scores Hold (48.0), and the composite conceals a 65-point disagreement between its dimensions. It is strongest on analyst consensus at 66, and weakest on competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 66 |
| technicals | 53 |
| competitive moat | 1 |
StoQuant analyzes 26 signals (22 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Galectin Therapeutics Inc. (GALT): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/GALT"><img src="https://stoquant.com/badge/GALT.svg" alt="Galectin Therapeutics Inc. (GALT) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.